Cloudbreak Pharmaceutical

Executive Summary

Cloudbreak Pharmaceutical is a privately held, pre-clinical stage ophthalmic drug company founded in 2015 and headquartered in Irvine, California. The company focuses on innovative ocular R&D, aiming to address significant unmet needs in eye disease treatment. With a dedicated research platform, Cloudbreak has built a pipeline of novel therapies targeting various ophthalmic conditions, though specific program details remain undisclosed. As a pre-clinical entity, the company's value hinges on advancing its lead candidates toward clinical development, securing intellectual property, and attracting partnerships or financing to support clinical trials. Given the early stage, Cloudbreak represents a high-risk, high-reward opportunity in the ophthalmic space, with potential for substantial upside if its pipeline progresses successfully.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for Lead Candidate40% success
• Q1 2027Preclinical Data Presentation at Major Ophthalmic Conference60% success
• H2 2026Series C Financing or Strategic Partnership35% success